Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* They are healthy infants based on medical history and clinical assessment.~* They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.~* Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.~Exclusion Criteria:~* Use of any investigational medicinal product prior to randomization.~* Previous vaccination against or infection with S. pneumoniae.~* History of anaphylactic shock or an allergic reaction to any prior vaccination.~* Any fever, illness (including malaria).~* Receipt of another vaccine within 30 days of study start.~* Chronic administration of an immunosuppressant or administration of immunoglobulins~* History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.~* History of meningitis, seizures or any neurological disorder.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- Pneumosil Lot 1 (Type: EXPERIMENTAL): Pneumosil Lot 1
- Pneumosil Lot 2 (Type: EXPERIMENTAL): Pneumosil Lot 2
- Pneumosil Lot 3 (Type: EXPERIMENTAL): Pneumosil Lot 3
- Synflorix (Type: ACTIVE_COMPARATOR): Synflorix

Based on this trial design, predict the completion outcome and termination type (if applicable).